Core Points - The Company announced the commencement of a subscription period for a Subsequent Offering of up to 22,222,222 new shares at a subscription price of NOK 0.90 per share [1] - The Board of Directors has decided to cancel the Subsequent Offering due to shares trading below the subscription price for a significant period, allowing shareholders to purchase shares at lower market prices [2] - Ensurge Micropower specializes in advanced microbattery technology for AI-enabled devices, focusing on thin-film batteries produced through high-precision roll-to-roll processes [3]

Core Insights - Kyverna Therapeutics, Inc. is set to host a live webcast and conference call on December 15, 2025, to discuss topline results from the Phase 2 KYSA-8 clinical trial for KYV-101 in stiff person syndrome [1][2] Company Overview - Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases, with its lead candidate KYV-101 advancing through late-stage clinical development [4] - KYV-101 is a fully human, autologous, CD19 CAR T-cell therapy designed for potency and tolerability, aiming for deep B-cell depletion and immune system reset [3][4] - The company is also conducting registrational trials for myasthenia gravis and has ongoing Phase 1/2 trials for lupus nephritis, with plans to explore additional indications such as multiple sclerosis and rheumatoid arthritis [4]

Core Insights - EVDANCE has released an expanded set of product recommendations and technical guidance for portable Level-1 and Level-2 EV chargers, addressing the growing need for safe and flexible home-charging solutions as electric vehicle ownership becomes more mainstream [1][15]. Product Recommendations - EVDANCE's updated recommendations aim to help EV owners select chargers that balance charging speed, safety, and convenience, suitable for various living situations including apartments and suburban homes [2]. - The recommended lineup includes three portable charging solutions: a 12A Level-1 unit, a 24A Level-2 dryer-outlet unit, and a 40A Level-2 smart charger, all available in Tesla-connector (NACS) and J1772 formats [4][19]. Charger Specifications - **12A Level-1 Charger**: Ideal for renters and users without 240V access, it operates at ~12A at 120V, suitable for overnight charging, and is ETL-listed with UL2594-aligned protections [5][6]. - **24A Level-2 Charger**: Designed for homeowners wanting a speed upgrade, it delivers up to 5.76 kW, providing approximately 20–25 miles of charge per hour, and connects to existing dryer outlets [7][8]. - **40A Level-2 Smart Charger**: Offers up to 9.6 kW for faster charging, features mobile app control for scheduling and monitoring, and is suitable for heavy daily mileage [9][10]. Safety and Certification - EVDANCE emphasizes the importance of device certification, specifically UL2594 and ETL testing, to ensure safety and performance for EV supply equipment in North America [3]. - Each charger includes built-in protections such as overcurrent and overvoltage protections, thermal management, and ground-fault detection, ensuring safe operation under various conditions [14][17][18]. Practical Use Cases - The 12A Level-1 model is recommended for renters and low-mileage drivers, while the 24A Level-2 units are suitable for multi-home owners and apartments with dryer outlets [11]. - The 40A smart charger is ideal for frequent long-distance drivers, and all portable chargers can serve as reliable backups during travel [12]. Interoperability - EVDANCE offers both NACS and J1772 connector versions across its product lineup, making the chargers compatible with various EV manufacturers and future-proof for mixed-fleet households [19]. Company Overview - EVDANCE is dedicated to creating safe, portable, and high-performance EV charging solutions, focusing on reliability and rigorous safety validation to meet the needs of diverse users [20].

Update on the Flamanville EPR: the reactor has reached 100% of nuclear thermal power 14 December 2025 marks a major milestone : the Flamanville 3 reactor reached 100% nuclear thermal power at 11:37am and generated 1,669MW of gross electrical power*. The ramp-up to 100% nuclear thermal power follows the approval by the French nuclear safety and radiation protection authority (ASNR) on 12 December 2025, to go beyond the 80% threshold. Reaching the 100% mark for the first time enables testing of equipment a ...

Core Viewpoint - InnoCare Pharma announced that the phase IIb clinical study of its BTK inhibitor orelabrutinib has successfully met its primary endpoint in treating systemic lupus erythematosus (SLE) and has received approval for a phase III trial [1][8]. Clinical Study Results - Orelabrutinib showed significant efficacy and a well-tolerated safety profile in SLE patients after 48 weeks of treatment, with 187 patients enrolled in the study [2][6]. - The primary endpoint, SLE Response Index-4 (SRI-4) response rate at week 48, was achieved with the 75 mg QD group showing a response rate of 57.1% compared to 34.4% in the placebo group (p < 0.05) [3]. - The 75 mg QD group also demonstrated better efficacy than the 50 mg QD group, indicating a dose-dependent improvement [3]. Secondary Endpoint and Subgroup Analysis - At week 48, the 75 mg QD group met secondary endpoints with significantly higher SRI-6 and BICLA response rates compared to placebo (p < 0.05) [4]. - In patients with baseline BILAG ≥1A or ≥2B, the placebo-adjusted difference in SRI-4 response rate for the 75 mg QD group was 35%, and for those with a clinical SLEDAI-2K score ≥4, it was 43% [5]. Safety Profile - Orelabrutinib was well tolerated among SLE patients, with a safety profile consistent with BTK inhibition and the disease's biology [6]. Market Potential and Company Overview - Orelabrutinib is the first BTK inhibitor to show significant efficacy in a phase II clinical trial for SLE, with expectations to become a first-in-class oral treatment [7]. - SLE affects approximately 8 million people globally, with around 1 million patients in China, highlighting a significant unmet medical need [8]. - InnoCare is focused on developing first-in-class and best-in-class drugs for cancer and autoimmune diseases, with operations in multiple locations including China and the United States [9].

Core Points - Rocket Lab Corporation successfully launched its first dedicated mission for the Japan Aerospace Exploration Agency (JAXA), marking a significant milestone for the Electron rocket in providing reliable access to space [1][2] - The "RAISE And Shine" mission deployed the RApid Innovative payload demonstration SatellitE-4 (RAISE-4), showcasing eight technologies developed by various Japanese entities [2] - This launch reflects the increasing collaboration between commercial companies and national space programs, with Rocket Lab being a leader in small launch services [3] Company Highlights - Rocket Lab's founder and CEO, Sir Peter Beck, emphasized the precision and reliability of the mission, supporting the growth of Japan's aerospace economy [4] - The "RAISE And Shine" mission was Rocket Lab's 19th launch of the year, contributing to a new annual launch record established just a month prior [4] - Upcoming launches include a second mission for JAXA scheduled for Q1 2026 and a dedicated launch for the European Space Agency (ESA) [3][4] Industry Context - The successful launch for JAXA illustrates the growing integration of commercial entities into national space initiatives, enhancing the global demand for Rocket Lab's Electron rocket [3] - Rocket Lab's Electron rocket is recognized as the world's most frequently launched orbital small rocket, indicating its strong position in the market [5]

Core Viewpoint - Exor's Board of Directors has unanimously rejected Tether's unsolicited proposal to acquire its controlling stake in Juventus Football Club, reaffirming its commitment to the club and its management strategy [1][2]. Group 1: Exor's Position on Juventus - Exor has consistently stated that it has no intention of selling any shares in Juventus to any third party, including Tether [2]. - The Agnelli family, as stable shareholders for over a century, remains fully committed to Juventus and supports its new management team [2]. Group 2: About Exor - Exor N.V. has been making successful investments worldwide for over a century, driven by a culture that combines entrepreneurial spirit and financial discipline [3]. - The company's portfolio includes major holdings in companies such as Ferrari, CNH, Stellantis, and Philips, where Exor is the largest shareholder [3].

Core Points - Robex Resources Inc. has filed an addendum to its management information circular regarding an arrangement agreement with Predictive Discovery Limited and Acquireco for the acquisition of all issued and outstanding common shares of Robex [1] - The special meeting for Robex shareholders to vote on the arrangement resolution is scheduled for December 30, 2025, following a postponement from December 15, 2025 [3][5] - The board of directors of Robex has unanimously recommended that shareholders vote in favor of the arrangement, stating that the amended consideration is fair from a financial perspective [4] Summary by Sections Arrangement Agreement - The addendum provides details about the amending agreement that modifies the previously announced arrangement agreement, where Acquireco will acquire all Robex shares through a statutory plan of arrangement [1] - Under the amended agreement, Robex shareholders will receive 7.862 Predictive shares for each Robex share held, resulting in approximately 53.5% ownership for existing Predictive shareholders and 46.5% for former Robex shareholders in the combined company [13] Meeting and Voting - The record date for determining eligible Robex shareholders to vote at the meeting is set for November 3, 2025 [2] - The deadline for depositing proxies has been extended to December 29, 2025, allowing shareholders additional time to submit their votes [8] - The meeting will be held virtually, and registration is required by December 22, 2025 [6] Financial Considerations - Cormark Securities Inc. and Canaccord Genuity Corp. provided fairness opinions confirming that the amended consideration is fair to Robex shareholders [13] - Pro forma capitalization and financial information have been updated to reflect the amended exchange ratio and are included in the addendum [15][21] Additional Information - An amended and restated circular has been filed to include previously omitted pro forma financial statements [29] - Robex has engaged financial and legal advisors to assist in the transaction process [31]

Core Viewpoint - Cornish Metals Inc. has received court approval for its re-domicile to the United Kingdom, facilitating the transfer of shares to a new entity, Cornish Metals plc, as part of a statutory plan of arrangement [1][2][3]. Group 1: Company Structure and Share Exchange - The arrangement involves exchanging one Cornish UK Share for every ten Cornish Canada Shares held, with rounding down to the nearest whole number [2]. - Shareholders with fewer than ten Cornish Canada Shares will receive no Cornish UK Shares [2]. - The transaction is expected to close around December 16, 2025, after satisfying customary closing conditions [3]. Group 2: Project Overview - Cornish Metals is advancing the South Crofty tin project, which is a historical underground tin mine in Cornwall, UK, and is the highest grade known tin resource not currently in production [6]. - The project is permitted for underground mining until 2071 and includes plans for a new processing facility and necessary site infrastructure [6]. - The South Crofty project could potentially be the first primary tin producer in Europe or North America, addressing the critical mineral demand as defined by various governments [6]. Group 3: Community and Economic Impact - The project is expected to generate over 300 direct jobs and has strong support from local communities and government [6].

Core Viewpoint - Fobi AI Inc. has received a partial revocation order from the British Columbia Securities Commission, allowing the company to proceed with a non-brokered private placement financing to raise up to C$1,500,000 [1][2] Group 1: Offering Details - The company plans to offer up to 30,000,000 units at a price of C$0.05 per unit, with each unit consisting of one common share and one share purchase warrant [1] - Each warrant will be exercisable to acquire an additional share at C$0.10 for 36 months from issuance [1] - The offering is expected to close around January 12, 2026, subject to necessary approvals [4] Group 2: Use of Proceeds - Proceeds from the offering will be allocated to accounting, audit, and legal fees for preparing continuous disclosure documents, filing fees for obtaining the revocation orders, employee salaries, operational expenses, and finder's fees [2] Group 3: Finder's Fees - The company may pay a cash commission of up to 7% of the gross proceeds to finders and may issue broker warrants of up to 7% of the units sold [3] Group 4: Regulatory Context - The common shares will remain subject to the cease trade order until a full revocation is granted, and the partial revocation does not guarantee future full revocation [5] - The securities will not be registered under U.S. securities laws and cannot be offered or sold in the U.S. without registration or an exemption [6] Group 5: Company Overview - Fobi AI Inc. specializes in data and AI technology, facilitating digital transformation through real-time data and mobile-wallet engagement across various industries [7]